Visual summary
Dialysis timing, modality, clearance, and fluid removal answer four different clinical questions; prescribe and reassess each explicitly.
Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.
Diagram description
Are complications refractory to medical treatment?. Immediate threat — Hyperkalemia, pulmonary edema, severe acidemia or uremic complications; No refractory complication — Follow trajectory and reassess; creatinine alone is not a start order; KRT is needed — Choose a modality the circulation and care setting can support. Monitor delivered treatment and recovery; reassess the continuing need for KRT. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.
Text version
Reassess the dialysis decision daily
Reassess the need for dialysis at least daily, and immediately with clinical deterioration. Base the decision on potassium and acid–base control, volume and oxygenation, uremic complications, relevant intoxications, trajectory and response to medical treatment. If these remain adequately controlled, continue treatment and monitoring rather than starting dialysis because of AKI stage, creatinine or elapsed time. Start promptly when an indication develops; reassessment must not delay urgently needed treatment.
In STARRT-AKI, accelerated initiation in critically ill patients without an immediate mandatory indication did not improve 90-day survival and caused more adverse events. This supports an indication-based decision with repeated reassessment, not an automatic early start and not indefinite postponement. KDIGO’s 2026 AKI/AKD update remains a draft being prepared for publication, as verified October 29, 2026.
STARRT-AKI, 2020 — PubMed · KDIGO AKI guideline and 2026 update status
Start for a complication
Urgent KRT is indicated when hyperkalemia, severe acid–base disturbance, pulmonary edema, or uremic complications cannot be controlled adequately by medical treatment. Assess the trajectory and the ability to sustain treatment; no creatinine or BUN value is a universal trigger.
Stable severe AKI is a different question
STARRT-AKI tested accelerated versus standard initiation in critically ill patients without an immediate mandatory indication. Accelerated treatment did not improve 90-day survival. This supports close observation in suitable patients, not delay during a life-threatening complication.
Choose a tolerable modality
Intermittent hemodialysis can correct solute abnormalities quickly but may cause abrupt hemodynamic shifts. CRRT permits slower continuous fluid/solute removal and is often chosen for instability or cerebral edema risk. Prolonged intermittent approaches can bridge practical needs.
Prescribe delivered treatment
For CRRT, KDIGO recommends a delivered effluent dose of 20–25 mL/kg/h; downtime means prescribed dose may need to be higher. Higher intensity has not improved survival. Separately prescribe net fluid removal according to congestion, refill, and perfusion.
Monitor more than creatinine
Track potassium, phosphate, magnesium, acid–base status, temperature, nutrition, circuit function, and bleeding/anticoagulation risk. Adjust antimicrobial dosing to modality and interruption time. A running circuit does not guarantee the intended clearance was delivered.
Reassess continuing need
Review spontaneous urine output, solute/acid control, volume needs, and recovery between treatments. Stop when intrinsic function can meet the patient’s needs. Published 2012 recommendations and modern trials are distinct from the KDIGO 2026 public-review draft.
